Stuart ASV, Shaw RH, Liu X, Greenland M, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 2021 Dec 6. pii: S0140-6736(21)02718.
PMID: 34883053